In a report issued on March 10, Thomas Shrader from BTIG maintained a Buy rating on Stoke Therapeutics (STOK – Research Report), with a price target of $83.00. The company’s shares closed last Friday at $26.10.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of -0.3% and a 31.9% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Aldeyra Therapeutics, and Sigilon Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $61.60 average price target, representing a 162.9% upside. In a report issued on March 16, Bank of America Securities also maintained a Buy rating on the stock with a $40.00 price target.
Stoke Therapeutics’ market cap is currently $975.1M and has a P/E ratio of -11.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Read More on STOK: